Attention Investors: Beware of fraudulent Calls, SMS, Emails, WhatsApp & Telegram messages assuring high returns and / or enticing you to invest money in the name of Aditya Birla Money by installing fake App from spurious links. You can download our Elevate App only from Google Play Store or Apple App Store or login to Elevate Web portal. Click Here to know more.
Experience finance made simple on the new ABCD app!
Scan to Download the App
One stop solution for all stock market enthusiasts
Whatsapp us!! We are Available.
Send HI on 8828800038
For Broking services
Call Toll Free Number :
1800-270-7000
( Mon - Fri: 9AM - 11PM )
( Sat & Sun: 9AM - 09PM )
Call N Trade
Call :
1800-108-9999 & Dial 1
( 9AM to 11:30PM )
Acquire & service self-trading online & offline clients. Archive large-scale business success with the entire product range offered by us.
Earn while you refer client. No need to set up your own infrastructure.
Join our referral program, earn rewards when friends and family open accounts & transact. Spread the word, multiply your earnings!
Join the Entrepreneurial Tribe!
Aditya Birla Money Limited
Symbol : AJANTPHARM | BSE Code : 532331 | Sector : PHARMACEUTICALS - INDIAN - FORMULATIONS
Market Cap (₹ Cr.)
Turnover (₹ Cr.)
05/08/2025 BSE -56.80(-2.11)Close Price: ₹ 2,637.60 Volume: 1,644.00
05/08/2025 BSE -56.45(-2.05)Close Price: ₹ 2,694.40 Volume: 2,139.00
05/08/2025 BSE -49.80(-1.78)Close Price: ₹ 2,750.85 Volume: 6,142.00
05/08/2025 BSE -21.50(-0.76)Close Price: ₹ 2,800.65 Volume: 4,666.00
05/08/2025 BSE 50.70(1.83)Close Price: ₹ 2,822.15 Volume: 6,951.00
No Data Available
Pls find enclosed Written Transcript of Earnings Call held on 28th July 2025.
Ajanta Pharma Ltd - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Ajanta Pharma Ltd - Announcement under Regulation 30 (LODR)-Newspaper Publication
Ajanta Pharma allots 23,525 equity shares under ESOP
In Cr.
Ajanta Pharma Limited is a specialty pharmaceutical formulation company primarily with a well-diversified Branded Generics business spread across India, the Rest of Asia, and Africa. The Company is involved in development, manufacturing and marketing of quality finished dosages in domestic and international markets. It produces a comprehensive range of specialty products targeting different therapeutic segments. It has strong chronic-focused product portfolio led by a first-to-market strategy and front-end presence which helps it outgrow the market. The company's business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia. In India, the Company has presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain management.In branded generic business in emerging markets in Asia and Africa, Ajanta Pharma's products cater to therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products. The company's institutional business comprises of supplies to various government bodies in India and supply of Anti-Malarial products under WHO approved programs in Africa.Ajanta Pharma operates 7 state-of-the-art manufacturing facilities in India and Mauritius. 2 of the facilities in India have been approved by USFDA. The company has an advanced Research & Development Centre in Mumbai for finished formulations and Active Pharmaceutical Ingredient (API) synthesis of different dosage forms. Its R&D centre has a team of over 750 scientists working on innovative products for various markets across the globe. Established in 1973 and headquartered in Mumbai-India, the company has a mission of Serving Global Health Care Needs Worldwide. Aja